CAS: 1195765-45-7
Product Features:
Targeted Inhibition of BRAF Mutations: Dabrafenib is specifically designed to treat cancers harboring BRAF V600E or V600K mutations. It selectively targets these mutant BRAF proteins and inhibits tumor growth.
Lower Side Effects: Compared with traditional chemotherapy, dabrafenib has more manageable side effects and is less likely to cause bone marrow suppression or gastrointestinal discomfort.
Strong Anti-Tumor Activity: In clinical trials, dabrafenib has demonstrated significant efficacy in treating BRAF-mutated tumors, including melanoma, non-small cell lung cancer, and colorectal cancer.
Combination Therapy: It is often used in combination with other targeted drugs (such as the MEK inhibitor trametinib) to enhance efficacy and prevent drug resistance.
